|
m16-067: a multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy
|
12-09-201911-09-2024
|
Penyelidik Bersama
|
|
m16-066:a multicenter,randomized,double-blind,placebo-controlled 52-week maintenance and an open label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis who responded to induction treatment in m16-067 0r 065
|
12-09-201911-09-2024
|
Penyelidik Bersama
|
|
combined phase 3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active crohn`s disease
|
16-03-201715-07-2024
|
Penyelidik Bersama
|
|
m14-675: a multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active ulcerative colitis
|
13-06-201912-06-2024
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study of mirikizumab in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis(protocol no: 16t-mc-aman)
|
27-12-201826-10-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease
|
14-09-201713-07-2023
|
Penyelidik Bersama
|
|
a randomized controlled trial to determine the effects of diabetes-specific formula on glycemic control in individuals with type 2 diabetes
|
08-03-202030-06-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo controlled maintenance and long term extension study of the efficacy and safety of upadacitinib (abt-494) in subjects with crohn’s disease who completed the m14-431 or m14-433 studies
|
12-04-201811-04-2023
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel-arm, placebo-controlled maintenance study of mirikizumab in patients with moderately to severely active ulcerative colitis.protocol no: 16t-mc-ambg
|
27-12-201826-02-2023
|
Penyelidik Bersama
|
|
a phase 3 multicenter, open-label extension (ole) study to evaluate the long-term safety and efficacy of abt-494 in subjects with ulcerative colitis (uc)
|
16-02-201715-02-2023
|
Penyelidik Bersama
|
|
a randomized controlled trial to determine the effects of a diabetes-specific formula on long-term glycemic control and short-term glycemic variability in individuals with type 2 diabetes
|
07-01-202106-01-2023
|
Penyelidik Bersama
|
|
a long-term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis
|
13-04-201712-12-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with crohn`s disease who responded to induction treatment in m16-006 or m15-991
|
26-10-201725-11-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease who failed prior biologic treatment
|
14-09-201713-10-2022
|
Penyelidik Bersama
|
|
randomized,24 week,active-controlled,open-label,3-arm.parallel-group multicenter study comparing the efficacy and safety of iglarlixi to insulin glargine and lixisenatide in type 2 diabetes mellitus patients insufficiently controlled with oral antidiabet
|
13-09-201912-07-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn’s disease who have inadequately responded to or are intolerant to
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn`s disease who have inadequately responded to or are intolerant to biologi
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of abt-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis
|
16-02-201715-02-2022
|
Penyelidik Bersama
|
|
combined phase 2b/3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis
|
13-04-201712-02-2022
|
Penyelidik Bersama
|
|
phase iii, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared with adalimuman and placebo in patients with moderate to severe ulcerative coliti
|
26-02-201525-12-2021
|
Penyelidik Bersama
|
|
an experimental pilot study: safety, feasibility and physiological response of relative hypoglycemia to the hormone, heart and brain in type 2 diabetes mellitus
|
25-07-202024-12-2021
|
Penyelidik Bersama
|
|
the genetics of adrenal gland diseases causing hyoertension
|
01-05-201530-04-2018
|
Penyelidik Bersama
|